0.38 USD
▼+0.00-0.13%
2026-08-03
市值
$5.59M
市盈率
—
EPS
-1.57
股息率
—
52 周区间
0.28 – 6.23
成交量
249.21K
Beta
1.92
目标价
1.75
52W 低 0.2852W 高 6.23
价格走势
公司简介
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment ...